Polymerase Chain Reaction in the Diagnosis and Prognosis of Mediterranean Visceral Leishmaniasis in Immunocompetent Children

Antonio Cascio, MD*; Sara Calattini, BSc‡; Claudia Colomba, MD*; Chiara Scalimogna, MD‡; Morena Galazzi, BSc‡; Massimo Pizzuto, MD‡; Romina Camilli, MD§; Marina Gramiccia, MD§; Lucina Titone, MD*; Mario Corbellino, MD‡; and Spinello Antinori, MD*

ABSTRACT. Objective. To assess the usefulness of a polymerase chain reaction (PCR) assay amplifying the small subunit rRNA coding region of Leishmania species performed on peripheral blood (PB) and bone marrow (BM) aspirates for the diagnosis and follow-up of visceral leishmaniasis (VL) in children living in the Mediterranean basin.

Design. A prospective study was conducted on children consecutively hospitalized over a 1-year period at our Infectious Diseases Department in Sicily (Italy) presenting with fever, hepatosplenomegaly, and/or pancytopenia and a positive Leishmania serology (≥1:40).

Results. Among the 14 patients hospitalized with signs and symptoms suggestive of the disease and a positive serology, we identified 10 cases of Mediterranean VL. PCR performed on PB and BM aspirates was positive in all cases and concordant with microscopy and/or culture performed on BM. Leishmania DNA was cleared from PB a median of 6 days after the start of treatment; during follow-up (median: 9 months; range: 6–12 months) 1 child relapsed. In this case, BM PCR remained positive with rapid reappearance of a positive signal also in PB.

Conclusions. PB PCR allows a rapid and noninvasive parasitologic diagnosis of Mediterranean VL among immunocompetent children and is at least as sensitive as a diagnosis made on the basis of BM aspirates. The lack of disappearance from BM and the reappearance of positive PCR on PB is predictive of clinical relapse. Qualitative and semiquantitative PCR may be the standard method for monitoring response to therapy in immunocompetent children. Pediatrics 2002;109(2). URL: http://www.pediatrics.org/cgi/content/full/109/2/e27; visceral leishmaniasis, polymerase chain reaction, diagnosis, peripheral blood, bone marrow.

ABBREVIATIONS. VL, visceral leishmaniasis; BMA, bone marrow aspirate; PB, peripheral blood; PCR, polymerase chain reaction; HIV, human immunodeficiency virus; RFLP, restriction fragment length polymorphism; BM, bone marrow.

From the *Istituto di Patologia Infettiva e Virologia, Ospedale dei Bambini G. di Cristina, Universita` di Palermo, Italy; ‡Istituto di Malattie Infettive e Tropicali, Ospedale L. Sacco, Universita` di Milano; and §Istituto Superiore di Sanita`, Roma, Italy. Received for publication Jul 26, 2001; accepted Oct 19, 2001. Reprint requests to (S.A.) Istituto di Patologia Infettiva e Virologia, Ospedale dei Bambini “G di Cristina”, Piazza Montalto 8, Palermo Italy. E-mail: spanitin@tin.it

PEDIATRICS (ISSN 0031-4005). Copyright © 2002 by the American Academy of Pediatrics.

http://www.pediatrics.org/cgi/content/full/109/2/e27
polymerism (RFLP) analysis of a repetitive Leishmania-specific nuclear genomic sequence obtained as described by Minodier et al.9–11 When available, identification results were compared with the standard isoenzyme characterization data.12

Serology was obtained by means of indirect immunofluorescence antibody test using a commercial kit (Leishmania Spot IF, Biomerieux, Marcy L’Etoile, France) and was performed at the time of diagnosis, 4 weeks later, and at each patient’s last follow-up visit.

All of the patients with VL were randomly assigned to a specific anti-Leishmania treatment as a part of a multicenter treatment study coordinated by the Istituto Superiore di Sanità, Rome, Italy, and designed to compare a pentavalent antimonial (meglumine antimoniate, Glucantime, Aventis Pharma, Milan, Italy) at a dose of 20 mg Sb5/kg/day given intramuscularly for 28 days versus liposomal amphotericin B (Ambisome, Gilead, San Diego, CA) at a dose of 3 mg/kg/day intravenously for 5 days followed by 1 additional administration after 1 week.

The study was approved by the local ethics committee, and the parents gave informed consent before the enrollment of the children in the study.

RESULTS

One hundred fourteen PB and 27 bone marrow (BM) samples taken from 14 immunocompetent children were tested. Overall, 10 patients were diagnosed as having VL; the remaining 4 patients (all of whom underwent bone marrow aspiration) had acute leukemia (2 cases) and infectious mononucleosis (2 cases). PCR performed either on PB and BMA in these 4 patients had negative results. Table 1 summarizes the parasitologic, serologic Leishmania zymodeme, and PCR studies conducted on the patients with confirmed VL. In all cases, PCR detected Leishmania in all BM (9/9) and PB (10/10) samples at first diagnosis; semiquantitative PCR analysis showed that the parasite load was at least 1 log higher in the BM samples of 8 cases (Fig 1), and comparable with the PB and BM samples of the remaining 2 patients. Microscopy revealed Leishmania amastigotes in 9 of 10 BM samples, whereas culture gave positive results in 8 of 8 cases. PCR-RFLP analysis for Leishmania species identification was performed for all patients and showed a single 250-bp band suggestive of L infantum infection (Fig 2). Eight Leishmania stocks isolated in culture from BMAs were identified by isoenzyme analysis as L infantum zymodeme MON1.

The patients were monitored during and after treatment for a median of 9 months (range: 6–12 months). The PB parasitemia detected by PCR was short-lived, and in all patients the assay became negative after a median of 6 days. However, the clearance of PB parasitemia was more rapid and statistically significant in the patients treated with liposomal amphotericin than in those treated with meglumine antimoniate (median: 6 days vs 14 days; P < .03; Mann-Whitney U test). Leishmania PCR on PB remained negative during the follow-up in all but 1 patient (who is described in greater detail below).

During the follow-up anti-Leishmania serology was unrevealing; in fact, 1 month after the first diagnosis, antibody titers remained unchanged (4 patients) or showed a slight decrease (6 patients). At the last follow-up visit, serology reverted to negativity in 1 patient only, whereas the antibody titers were still unchanged in 2 children, had increased in 2, and had decreased in the remaining 5 patients.

| TABLE 1. Characteristics of Children With Mediterranean VL | Age (Months) | Sex | Therapy | Microscopy | Culture | Serology | Follow-up (Months) | PCR | BM | Leishmania | Zydomere | VL-Relapse (Weeks) | Number |
|-----------------------------------------------------------|-------------|-----|---------|------------|---------|----------|-------------------|-----|----------------|-----------|-------------------|---------|-------------|----------|
| Patient Number | 1 | 19 | F | Meglumine antimoniate | Positive (BM) | L infantum | Positive (BM) | Positive | Posit | 1:320 | Positive | Positive | No | 12 |
| | 2 | 24 | F | Meglumine antimoniate | Positive (BM) | L infantum | Positive (BM) | Positive | Posit | 1:320 | Positive | Positive | No | 6 |
| | 3 | 16 | F | Meglumine antimoniate | Positive (BM) | L infantum | Positive (BM) | Positive | Posit | 1:320 | Positive | Positive | No | 12 |
| | 4 | 17 | M | Liposomal amphotericin B | Positive (BM) | L infantum | Positive (BM) | Positive | Posit | 1:320 | Positive | Positive | No | 12 |
| | 5 | 50 | F | Liposomal amphotericin B | Positive (BM) | L infantum | Positive (BM) | Positive | Posit | 1:320 | Positive | Positive | No | 12 |
| | 6 | 12 | F | Liposomal amphotericin B | Positive (BM) | L infantum | Positive (BM) | Positive | Posit | 1:320 | Positive | Positive | No | 9 |
| | 7 | 9 | M | Liposomal amphotericin B | Positive (BM) | L infantum | Positive (BM) | Positive | Posit | 1:320 | Positive | Positive | No | 9 |
| | 8 | 12 | F | Liposomal amphotericin B | Positive (BM) | L infantum | Positive (BM) | Positive | Posit | 1:320 | Positive | Positive | No | 9 |

*Indicates skin scraping; MON, Montpellier nomenclature; ND, not done.

* On the second day of treatment, the patient had a generalized urticaroid reaction; Meglumine antimoniate was stopped, and the next day she was started on liposomal amphotericin.
Case 10

A 9-month-old child was admitted to our ward with a 15-day history of high fever (40°C) and cough. On physical examination, he was febrile and pale, and had an enlarged liver (5 cm below the right costal margin), and splenomegaly (8 cm below the left costal margin). Laboratory values were as follows: hemoglobin: 8.7 g/dL; platelets 98,000/µL; and C-reactive protein: 2 mg/dL. *Leishmania* serology was positive at a titer of 1:320; a BMA showed several *Leishmania* amastigotes. The patient was randomized to receive a 28-day course of meglumine antimoniate (60 mg/kg/d, total dose 504 mg). Defervescence occurred on the sixth day of therapy. At the end of the treatment PB PCR was negative, the hematologic values had risen (Hb 10.2 g/dL; platelets 252,000/µL), and the hepatosplenomegaly was reduced. No culture was performed, but microscopic examination of a posttreatment BMA indicated parasitologic cure and so the patient was discharged despite the fact that PCR on BM was still positive. At the first follow-up visit (third month), the child was in apparent good health and still afebrile, and his weight had increased from 8.4 kg to 12 kg. At this time, PCR on PB was again positive. Fifteen days later, the child was readmitted to our hospital with persistent fever (39°C), an enlarged spleen (5 cm below the left costal arch), and anemia (Hb 8.8 g/dL). An additional BMA showed numerous intracellular and extracellular *Leishmania* amastigotes; the PB and BM PCRs were still positive with the latter showing an increase of parasite load in comparison with the pretreatment sample (Fig 1). The patient was treated with liposomal amphotericin B (Ambisome 3 mg/kg/d) for 10 days and showed defervescence on the third day. PCR on PB became negative 1 week after the start of treatment. One month later, microscopy of BM smears was negative and both BM and PB
were PCR-negative; at the last follow-up visit (4 months after the new treatment) PB PCR was still negative.

DISCUSSION

PCR on PB, BM, and lymph node aspirates has been increasingly used as a rapid, sensitive, and specific method for the diagnosis of VL mainly in immunocompromised patients. In immunocompetent host, Nuzum et al. have reported a 90% sensitivity of PB PCR in parasitologically confirmed cases of kala-azar from 2 areas endemic for Leishmania donovani (India and Africa) and 1 endemic for Leishmania chagasi (Brazil). Other researchers from Sudan detected Leishmania DNA by PCR in the PB of 70% of their patients with confirmed VL.

To the best of our knowledge, the use of PCR performed on PB (whole blood and buffy coat) and BMA for the diagnosis of VL in pediatric patients has been previously reported in the case of 13 children from France and 12 from China. In the former study, Minodier et al. detected Leishmania DNA by PCR in 5 of 5 BM samples and 3 of 7 PB samples taken from 8 children with VL. In a more recent study from France, the investigators reported concordant and positive PCR results on PB and BM samples from 3 immunocompetent children (in 1 case, the cultures remained negative and diagnosis was confirmed by other methods), and concordant positive PCR and culture results in 1 patient for whom only PB was available. In the study conducted in China, primary or nested PCR was positive on 9 of 10 BM and in 7 of 11 PB (buffy coat) specimens.

The aims of our study were to compare the results of PB and BM PCR with those of standard parasitologic methods of diagnosing VL and, mainly, to evaluate the usefulness of this molecular method in assessing definitive parasitologic cure after treatment. Our results confirm the reliability of Leishmania PCR performed on PB in the diagnosis of VL; the high level of sensitivity was reflected by the ability of the assay to detect parasite DNA in PB of patients with VL in all cases, a result that was better than microscopy and equal to culture performed on BMAs.

Our results also show that parasitemia in PB is usually short-lived in immunocompetent children receiving antileishmanial treatment (a median of 6 days to achieve PCR negativity). In addition, we demonstrated that the persistence of a positive BM PCR is followed by the rapid reappearance of Leishmania parasites in PB and, ultimately, clinically overt disease relapse. As expected, in the majority of cases (all but 2 patients), the PB parasite load was less than in BM; furthermore, the rapid disappearance of PB parasitemia in this group of immunocompetent children contrasts with what we have previously observed in immunocompromised HIV-positive patients, in whom PB parasitemia became negative under treatment after a median of 5 weeks. Although in our study the number of treated children with the 2 regimes was limited, we observed a statistically significant more rapid clearance of blood parasitemia in the group assigned to liposomal amphotericin B; however, larger series of patients should be examined before any definitive conclusions can be drawn concerning the relative efficacy of either drug.

It has long been accepted that few or no circulating Leishmania parasites are present in patients with Mediterranean VL. However, a number of recent studies have reported the detection L. infantum in PB of patients coinfected with HIV. Our study confirms the frequent presence of circulating parasites during the course of VL also in immunocompetent individuals and extends this finding to immunocompetent children. Moreover, PCR-RFLP analysis identified the etiologic agent as L. infantum in all cases, a finding later confirmed by the standard method of Leishmania biochemical characterization.

Physicians are probably still not confident about replacing BM examination with PB PCR for the diagnosis of VL. However, we believe that this method should be considered the gold standard for monitoring parasitologic cure because it is easy to perform, noninvasive (thus allowing frequent sampling), well accepted by patients (especially children), and more reliable than microscopy and serology, and more rapid than traditional culture. Finally, patient monitoring by means of Leishmania-specific PCR in the blood can predict treatment failure in a timely manner, and thus allow prompt and appropriate therapeutic adjustments.

ACKNOWLEDGMENTS

This work was supported, in part, by a grant from MURST (ex 60%).

REFERENCES


4 of 5 VISCERAL LEISHMANIASIS DIAGNOSED BY POLYMERASE CHAIN REACTION


